Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Nephros appoints Andy Astor as president, CEO » 07:36
08/14/20
08/14
07:36
08/14/20
07:36
NEPH

Nephros

$7.69 /

+0.04 (+0.52%)

Nephros announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NEPH Nephros
$7.69 /

+0.04 (+0.52%)

NEPH Nephros
$7.69 /

+0.04 (+0.52%)

01/06/20 Benchmark
Benchmark names Alibaba, Nvidia, Comcast among best ideas for first half
10/24/19 Benchmark
Nephros initiated with a Speculative Buy at Benchmark
10/04/19 Maxim
Nephros initiated with a Buy rating at Maxim
NEPH Nephros
$7.69 /

+0.04 (+0.52%)

  • 31
    Jan
Yesterday
Recommendations
Biocept price target raised to $2 from $1 at Maxim » 08:45
08/13/20
08/13
08:45
08/13/20
08:45
BIOC

Biocept

$1.02 /

+0.015 (+1.49%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy raised the firm's price target on Biocept to $2 from $1 and keeps a Buy rating on the shares. The analyst notes that the 37% decline in the company's Q2 revenue was due to the "temporary" impact of COVID-19 on oncology testing, though the COVID-19 related testing which Biocept had entered in late June should play a larger role in sales in Q3 and beyond.

ShowHide Related Items >><<
BIOC Biocept
$1.02 /

+0.015 (+1.49%)

BIOC Biocept
$1.02 /

+0.015 (+1.49%)

05/14/20 Brookline
Biocept initiated with a Buy at Brookline
  • 14
    Apr
Hot Stocks
Biocept enters pact with healthcare group to provide COVID-19 testing » 08:08
08/13/20
08/13
08:08
08/13/20
08:08
BIOC

Biocept

$1.02 /

+0.015 (+1.49%)

Biocept announces it has…

Biocept announces it has entered into an agreement with a healthcare group to provide COVID-19 testing to skilled nursing facilities. The group operates and supports more than 50 facilities in multiple states, with most located in California, the state with one of the most stringent COVID-19 testing regulations in the U.S. Several of the skilled nursing facilities have implemented Biocept's cutting-edge, new online ordering system for ease-of-use to customers. Biocept's new systems makes COVID-19 test ordering efficient for clients and streamlines the front-end onboarding process within Biocept's CLIA laboratory, allowing increased testing capacity and decreased costs. Biocept believes its test performance, quality and customer service are ideal for supporting healthcare facilities to care for their residents and patients as they stay compliant with state mandates.

ShowHide Related Items >><<
BIOC Biocept
$1.02 /

+0.015 (+1.49%)

BIOC Biocept
$1.02 /

+0.015 (+1.49%)

05/14/20 Brookline
Biocept initiated with a Buy at Brookline
  • 14
    Apr
Hot Stocks
TransEnterix names Shameze Rampertab as CFO, effective August 24 » 06:59
08/13/20
08/13
06:59
08/13/20
06:59
TRXC

TransEnterix

$0.44 /

-0.01 (-2.23%)

, ZOM

Zomedica

$0.15 /

-0.0032 (-2.12%)

TransEnterix (TRXC)…

TransEnterix (TRXC) announced that Shameze Rampertab has been appointed as the company's Executive Vice President and CFO, effective August 24. Most recently, Rampertab served as interim CEO (December 2019 to June 2020), CFO (March 2016 to August 2020), and Corporate Secretary and a director (April 2016 to August 2020) at Zomedica Pharmaceuticals (ZOM).

ShowHide Related Items >><<
ZOM Zomedica
$0.15 /

-0.0032 (-2.12%)

TRXC TransEnterix
$0.44 /

-0.01 (-2.23%)

TRXC TransEnterix
$0.44 /

-0.01 (-2.23%)

ZOM Zomedica
$0.15 /

-0.0032 (-2.12%)

06/17/20 H.C. Wainwright
Zomedica price target lowered to 50c from 65c at H.C. Wainwright
  • 02
    Jul
  • 05
    Sep
TRXC TransEnterix
$0.44 /

-0.01 (-2.23%)

Wednesday
Conference/Events
Oppenheimer to hold a virtual conference » 04:55
08/12/20
08/12
04:55
08/12/20
04:55
CTL

CenturyLink

$11.05 /

+0.18 (+1.66%)

, RESN

Resonant

$2.40 /

-0.165 (-6.43%)

, LPSN

LivePerson

$57.56 /

-0.23 (-0.40%)

, ZEN

Zendesk

$85.27 /

-2 (-2.29%)

, FEYE

FireEye

$15.28 /

-0.69 (-4.32%)

, VG

Vonage

$11.95 /

-0.26 (-2.13%)

23rd Annual Technology,…

23rd Annual Technology, Internet & Communications Conference will be held on August 11-12.

ShowHide Related Items >><<
ZEN Zendesk
$85.27 /

-2 (-2.29%)

VG Vonage
$11.95 /

-0.26 (-2.13%)

RESN Resonant
$2.40 /

-0.165 (-6.43%)

LPSN LivePerson
$57.56 /

-0.23 (-0.40%)

FEYE FireEye
$15.28 /

-0.69 (-4.32%)

CTL CenturyLink
$11.05 /

+0.18 (+1.66%)

CTL CenturyLink
$11.05 /

+0.18 (+1.66%)

07/15/20 Oppenheimer
CenturyLink downgraded to Perform at Oppenheimer on negative trends amid COVID
07/15/20 Oppenheimer
CenturyLink downgraded to Perform from Outperform at Oppenheimer
05/08/20 RBC Capital
CenturyLink price target lowered to $10 from $14 at RBC Capital
04/02/20 Guggenheim
Guggenheim upgrades CenturyLink to Neutral, sees fundamentals holding up well
RESN Resonant
$2.40 /

-0.165 (-6.43%)

02/28/20
Fly Intel: Top five analyst initiations
02/28/20 Stifel
Resonant initiated with a Buy at Stifel
LPSN LivePerson
$57.56 /

-0.23 (-0.40%)

08/05/20 B. Riley FBR
LivePerson price target raised to $63 from $49 at B. Riley FBR
08/05/20 Barclays
LivePerson price target raised to $64 from $49 at Barclays
08/05/20 Craig-Hallum
LivePerson price target raised to $60 from $34 at Craig-Hallum
08/05/20 Roth Capital
LivePerson price target raised to $75 from $53 at Roth Capital
ZEN Zendesk
$85.27 /

-2 (-2.29%)

07/31/20 RBC Capital
Zendesk price target lowered to $110 from $120 at RBC Capital
07/31/20 Jefferies
Zendesk price target raised to $113 from $91 at Jefferies
07/30/20 Wells Fargo
Zendesk price target raised to $120 from $95 at Wells Fargo
07/21/20 RBC Capital
Zendesk price target raised to $120 from $100 at RBC Capital
FEYE FireEye
$15.28 /

-0.69 (-4.32%)

07/29/20 JPMorgan
FireEye price target raised to $18 from $15 at JPMorgan
07/29/20 Mizuho
FireEye price target raised to $17 from $15 at Mizuho
04/13/20 BMO Capital
FireEye price target lowered to $12.50 from $17 at BMO Capital
03/05/20
Fly Intel: Top five analyst upgrades
VG Vonage
$11.95 /

-0.26 (-2.13%)

08/06/20 Jefferies
Vonage price target raised to $12.50 from $11 at Jefferies
07/27/20 Rosenblatt
Vonage initiated with a Neutral at Rosenblatt
06/30/20 Stephens
Agora IPO spotlights undervaluing of Vonage's API growth, says Stephens
06/09/20
Fly Intel: Top five analyst downgrades
ZEN Zendesk
$85.27 /

-2 (-2.29%)

VG Vonage
$11.95 /

-0.26 (-2.13%)

RESN Resonant
$2.40 /

-0.165 (-6.43%)

LPSN LivePerson
$57.56 /

-0.23 (-0.40%)

FEYE FireEye
$15.28 /

-0.69 (-4.32%)

CTL CenturyLink
$11.05 /

+0.18 (+1.66%)

  • 07
    Feb
VG Vonage
$11.95 /

-0.26 (-2.13%)

LPSN LivePerson
$57.56 /

-0.23 (-0.40%)

FEYE FireEye
$15.28 /

-0.69 (-4.32%)

ZEN Zendesk
$85.27 /

-2 (-2.29%)

VG Vonage
$11.95 /

-0.26 (-2.13%)

LPSN LivePerson
$57.56 /

-0.23 (-0.40%)

FEYE FireEye
$15.28 /

-0.69 (-4.32%)

CTL CenturyLink
$11.05 /

+0.18 (+1.66%)

LPSN LivePerson
$57.56 /

-0.23 (-0.40%)

FEYE FireEye
$15.28 /

-0.69 (-4.32%)

CTL CenturyLink
$11.05 /

+0.18 (+1.66%)

Tuesday
Conference/Events
Oppenheimer to hold a virtual conference » 08:27
08/11/20
08/11
08:27
08/11/20
08:27
CTL

CenturyLink

$10.87 /

+0.38 (+3.62%)

, RESN

Resonant

$2.57 /

-0.01 (-0.39%)

, LPSN

LivePerson

$57.79 /

+0.3 (+0.52%)

, ZEN

Zendesk

$87.27 /

-1.08 (-1.22%)

, FEYE

FireEye

$15.97 /

+0.29 (+1.85%)

, VG

Vonage

$12.21 /

-0.32 (-2.55%)

23rd Annual Technology,…

23rd Annual Technology, Internet & Communications Conference will be held on August 11-12.

ShowHide Related Items >><<
ZEN Zendesk
$87.27 /

-1.08 (-1.22%)

VG Vonage
$12.21 /

-0.32 (-2.55%)

RESN Resonant
$2.57 /

-0.01 (-0.39%)

LPSN LivePerson
$57.79 /

+0.3 (+0.52%)

FEYE FireEye
$15.97 /

+0.29 (+1.85%)

CTL CenturyLink
$10.87 /

+0.38 (+3.62%)

CTL CenturyLink
$10.87 /

+0.38 (+3.62%)

07/15/20 Oppenheimer
CenturyLink downgraded to Perform at Oppenheimer on negative trends amid COVID
07/15/20 Oppenheimer
CenturyLink downgraded to Perform from Outperform at Oppenheimer
05/08/20 RBC Capital
CenturyLink price target lowered to $10 from $14 at RBC Capital
04/02/20 Guggenheim
Guggenheim upgrades CenturyLink to Neutral, sees fundamentals holding up well
RESN Resonant
$2.57 /

-0.01 (-0.39%)

02/28/20
Fly Intel: Top five analyst initiations
02/28/20 Stifel
Resonant initiated with a Buy at Stifel
LPSN LivePerson
$57.79 /

+0.3 (+0.52%)

08/05/20 B. Riley FBR
LivePerson price target raised to $63 from $49 at B. Riley FBR
08/05/20 Barclays
LivePerson price target raised to $64 from $49 at Barclays
08/05/20 Craig-Hallum
LivePerson price target raised to $60 from $34 at Craig-Hallum
08/05/20 Roth Capital
LivePerson price target raised to $75 from $53 at Roth Capital
ZEN Zendesk
$87.27 /

-1.08 (-1.22%)

07/31/20 RBC Capital
Zendesk price target lowered to $110 from $120 at RBC Capital
07/31/20 Jefferies
Zendesk price target raised to $113 from $91 at Jefferies
07/30/20 Wells Fargo
Zendesk price target raised to $120 from $95 at Wells Fargo
07/21/20 RBC Capital
Zendesk price target raised to $120 from $100 at RBC Capital
FEYE FireEye
$15.97 /

+0.29 (+1.85%)

07/29/20 JPMorgan
FireEye price target raised to $18 from $15 at JPMorgan
07/29/20 Mizuho
FireEye price target raised to $17 from $15 at Mizuho
04/13/20 BMO Capital
FireEye price target lowered to $12.50 from $17 at BMO Capital
03/05/20
Fly Intel: Top five analyst upgrades
VG Vonage
$12.21 /

-0.32 (-2.55%)

08/06/20 Jefferies
Vonage price target raised to $12.50 from $11 at Jefferies
07/27/20 Rosenblatt
Vonage initiated with a Neutral at Rosenblatt
06/30/20 Stephens
Agora IPO spotlights undervaluing of Vonage's API growth, says Stephens
06/09/20
Fly Intel: Top five analyst downgrades
ZEN Zendesk
$87.27 /

-1.08 (-1.22%)

VG Vonage
$12.21 /

-0.32 (-2.55%)

RESN Resonant
$2.57 /

-0.01 (-0.39%)

LPSN LivePerson
$57.79 /

+0.3 (+0.52%)

FEYE FireEye
$15.97 /

+0.29 (+1.85%)

CTL CenturyLink
$10.87 /

+0.38 (+3.62%)

  • 07
    Feb
VG Vonage
$12.21 /

-0.32 (-2.55%)

LPSN LivePerson
$57.79 /

+0.3 (+0.52%)

FEYE FireEye
$15.97 /

+0.29 (+1.85%)

ZEN Zendesk
$87.27 /

-1.08 (-1.22%)

VG Vonage
$12.21 /

-0.32 (-2.55%)

LPSN LivePerson
$57.79 /

+0.3 (+0.52%)

FEYE FireEye
$15.97 /

+0.29 (+1.85%)

CTL CenturyLink
$10.87 /

+0.38 (+3.62%)

LPSN LivePerson
$57.79 /

+0.3 (+0.52%)

FEYE FireEye
$15.97 /

+0.29 (+1.85%)

CTL CenturyLink
$10.87 /

+0.38 (+3.62%)

Monday
Earnings
Tonix Pharmaceuticals reports Q2 EPS (23c), two est. (22c) » 09:34
08/10/20
08/10
09:34
08/10/20
09:34
TNXP

Tonix Pharmaceuticals

$1.16 /

-0.04 (-3.33%)

"The second quarter…

"The second quarter was highlighted by exciting progress for our lead immunology and central nervous system product candidates," said Seth Lederman, M.D., President and Chief Executive Officer. "We expect to have the first data from animal studies of our lead COVID-19 vaccine candidate, TNX-1800, in the fourth quarter of this year. TNX-1800 is a live attenuated vaccine based on our proprietary horsepox vector system that carries a gene encoding the Spike protein from SARS-CoV-2, the virus that causes COVID-19. We have also continued to progress the Phase 3 RELIEF study of TNX-102 SL for fibromyalgia, having reached 50% enrollment in April and then completing enrollment in July, ahead of schedule. We look forward to interim data in September and topline results from the RELIEF study by the end of this year."

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$1.16 /

-0.04 (-3.33%)

TNXP Tonix Pharmaceuticals
$1.16 /

-0.04 (-3.33%)

08/30/19 Roth Capital
Tonix Pharmaceuticals price target lowered to $1.30 from $4 at Roth Capital
TNXP Tonix Pharmaceuticals
$1.16 /

-0.04 (-3.33%)

TNXP Tonix Pharmaceuticals
$1.16 /

-0.04 (-3.33%)

Over a week ago
Hot Stocks
Tonix Pharmaceuticals announces clearance of IND for TNX-102 SL » 09:01
08/06/20
08/06
09:01
08/06/20
09:01
TNXP

Tonix Pharmaceuticals

$1.26 /

+0.04 (+3.29%)

Tonix Pharmaceuticals…

Tonix Pharmaceuticals announced the U.S. Food and Drug Administration has cleared the Investigational New Drug application for the initiation of a Phase 2 proof-of-concept study using TNX-102 SL for treatment of alcohol use disorder. The program in AUD is expected to qualify for the 505(b)(2) pathyway for FDA approval.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$1.26 /

+0.04 (+3.29%)

TNXP Tonix Pharmaceuticals
$1.26 /

+0.04 (+3.29%)

08/30/19 Roth Capital
Tonix Pharmaceuticals price target lowered to $1.30 from $4 at Roth Capital
TNXP Tonix Pharmaceuticals
$1.26 /

+0.04 (+3.29%)

TNXP Tonix Pharmaceuticals
$1.26 /

+0.04 (+3.29%)

Hot Stocks
Biocept announces pact with Aegea Biotechnologies » 08:17
08/06/20
08/06
08:17
08/06/20
08:17
BIOC

Biocept

$0.89 /

+0.1044 (+13.36%)

Biocept and Aegea…

Biocept and Aegea Biotechnologies, "an innovative private life science company with an extensive portfolio of issued patents in next-generation nucleic acid technologies," announce a development agreement focused on the co-development by Biocept and Aegea of a highly sensitive PCR-based assay designed by Aegea for detecting the COVID-19 virus. The COVID-19 PCR assay is based on the core Switch-Blocker technology used in Biocept's suite of ultra-sensitive oncology-focused assays. The collaboration will leverage Biocept's experience in developing high-performance assays based on the Switch-Blocker technology. The COVID-19 PCR assay is being developed as a next-generation test designed for improved analytical performance in order to better assist healthcare providers in screening and managing patients. The test is designed to incorporate unique capabilities to increase the sensitivity in detecting SARS-CoV-2 and to provide additional information on specific strain types. As part of the development agreement, Biocept has first option to negotiate a license agreement to any resulting new COVID-19 PCR assay for commercialization in its CLIA-certified, CAP-accredited high-complexity molecular lab.

ShowHide Related Items >><<
BIOC Biocept
$0.89 /

+0.1044 (+13.36%)

BIOC Biocept
$0.89 /

+0.1044 (+13.36%)

05/14/20 Brookline
Biocept initiated with a Buy at Brookline
  • 14
    Apr
Earnings
Nephros reports Q2 EPS (19c), consensus (15c) » 17:24
08/05/20
08/05
17:24
08/05/20
17:24
NEPH

Nephros

$8.40 /

+ (+0.00%)

Reports Q2 revenue $1.6M,…

Reports Q2 revenue $1.6M, consensus $1.74M. As of June 30, Nephros had cash and cash equivalents of $7M.

ShowHide Related Items >><<
NEPH Nephros
$8.40 /

+ (+0.00%)

NEPH Nephros
$8.40 /

+ (+0.00%)

01/06/20 Benchmark
Benchmark names Alibaba, Nvidia, Comcast among best ideas for first half
10/24/19 Benchmark
Nephros initiated with a Speculative Buy at Benchmark
10/04/19 Maxim
Nephros initiated with a Buy rating at Maxim
NEPH Nephros
$8.40 /

+ (+0.00%)

  • 31
    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.